UPCOMING EVENTS
All seminars take place usually each Tuesday at 11 am at 11:00 AM in the meeting room “Philippe Jeanteur “.
- 2 July 2026
-
-
Robert S. ILLINGWORTH - Institute for Regeneration and Repair, University of Edinburgh
2 July 2026 10 h 30 min - 12 h 00 min
Institut de Génétique Moléculaire de Montpellier (IGMM), 1919 Rte de Mende, 34090 Montpellier, France
Title : Passive Yet Essential, Polycomb Repression in Development and Disease
Contact : carla.heredia@igmm.cnrs.fr -
Prof. Alan TALEVI (Universidad Nacional de La Plata, La Plata, Argentina)
2 July 2026 11 h 00 min - 12 h 00 min
Marcel Dorée Seminar RoomCRBM External Seminar
“Machine Learning and Structure-Based Approaches for the Discovery of Biomarkers and Bioactive Compounds”
Contact: andrey.kajava@crbm.cnrs.fr
-
- 3 July 2026
-
-
Vincent Loubière - IGH Montpellier
3 July 2026 13 h 00 min - 14 h 00 min
Institut de Génétique Moléculaire de Montpellier (IGMM), 1919 Rte de Mende, 34090 Montpellier, FranceTitle : “Epigenetic and cis-regulatory determinants of tumorigenesis"
Contact : nadine.laguette@igmm.cnrs.fr
-
- 17 July 2026
-
-
Seminar : Alexander Waclawiczek, DKFZ, Heidelberg, Germany
17 July 2026 11 h 00 min - 13 h 00 min
Institut de Génétique Moléculaire de Montpellier (IGMM), 1919 Rte de Mende, 34090 Montpellier, FranceTitle: The Genotype–Phenotype Relationship as Mediator of Therapy Resistance in Acute Myeloid Leukemia
Abstract:
Acute myeloid leukemia (AML) is characterized by extensive genetic and phenotypic heterogeneity. Leukemic stem cells (LSCs) are a self-renewing subpopulation of AML cells that sustains disease initiation, progression, and relapse. By translating the underlying pathogenic genotype into a malignant cellular phenotype and generating the progeny that constitute the bulk of the leukemia, LSCs lie at the interface between genotype and phenotype. Over the past decade, both genetic alterations and cellular phenotypes have emerged as important determinants of therapeutic response in AML. Deciphering how these features interact within LSCs may therefore provide new insights into treatment response, disease persistence, and the development of therapy resistance.Contact : guillaume.bossis@igmm.cnrs.fr
-


